Human papillomavirus are DNA viruses and are very commonly associated with benign and malignant proliferation of skin lesions that can progress to cancer. Because there are no antiviral drugs for HPV infection, current therapies involve physical removal of lesions. However, after these procedures, may recurrences appear due to new reinfections or to failure of the procedure to eliminate the HPV. In addition, HPV can inhibit recognition of malignant cells by the immune system leading to the development of cancer lesions. Novel Vaccinia virus vaccines which are highly attenuated can modulate and promote the generation of specific cytotoxic responses that are able to completely eliminate lesions and also induce the eradication of HPV virus from infected patients. Development of attenuated virus vaccines and strategies from clinical trials reports will be presented.

Ricardo Rosales completed his Ph.D at the age of 31 years from Louis Pasteur University, Strasbourg, France. Studies as Post-doctoral at the National Institutes of Health-Bethesda, USA. At present is the Director and head of the department of molecular biology at Virolab. He has over 30 publications that have been cited over 1500 times, and his publication h-index is 21. Currently is working with a collaborative and multidisciplinary team for the development of viral vector vaccines against papillomavirus, melanomas, hepatitis C, Herpes I and Herpes II.